Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its position in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 14.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 150,238 shares of the biotechnology company's stock after purchasing an additional 19,452 shares during the period. Bank of New York Mellon Corp owned approximately 0.28% of Prothena worth $2,081,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Prothena by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock worth $158,000 after purchasing an additional 1,065 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new stake in Prothena during the fourth quarter worth about $159,000. Intech Investment Management LLC purchased a new position in Prothena during the third quarter valued at approximately $210,000. XTX Topco Ltd acquired a new position in Prothena in the third quarter valued at approximately $260,000. Finally, Handelsbanken Fonder AB boosted its position in Prothena by 35.7% in the 4th quarter. Handelsbanken Fonder AB now owns 20,900 shares of the biotechnology company's stock worth $289,000 after purchasing an additional 5,500 shares in the last quarter. 97.08% of the stock is currently owned by hedge funds and other institutional investors.

Prothena Trading Down 5.2 %

Shares of NASDAQ PRTA traded down $0.69 during midday trading on Tuesday, reaching $12.65. 391,185 shares of the company were exchanged, compared to its average volume of 483,400. The stock has a fifty day simple moving average of $14.33 and a 200 day simple moving average of $15.75. The stock has a market cap of $680.91 million, a P/E ratio of -5.50 and a beta of -0.02. Prothena Co. plc has a 1 year low of $11.70 and a 1 year high of $26.36.

Remove Ads

Prothena (NASDAQ:PRTA - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). The business had revenue of $2.12 million for the quarter, compared to analysts' expectations of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. As a group, analysts forecast that Prothena Co. plc will post -4.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

PRTA has been the topic of a number of analyst reports. HC Wainwright restated a "buy" rating and set a $48.00 target price on shares of Prothena in a research report on Friday, February 21st. Oppenheimer boosted their price objective on Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a research report on Friday, February 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Prothena in a research report on Friday, February 21st. Chardan Capital reissued a "buy" rating and issued a $40.00 price target on shares of Prothena in a report on Friday, February 21st. Finally, Royal Bank of Canada decreased their price objective on shares of Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a report on Friday, February 21st. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $55.00.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.